Biotech grants in the United States

Open

Funds mathematics with real biological relevance — and asks for innovation on both sides plus genuine integration between them.

Open

Supports diverse early-career neuroscientists moving from mentorship to independent research leadership.

Open

Funds a clinical trial for psychological health conditions or traumatic brain injury, at a pilot or a larger effectiveness scale the applicant chooses.

Open

Funds translational research turning brain-injury or psychological-health findings into a real clinical application — short of running a clinical trial.

Open

Supports established United States companies with income tax credits tied to qualified innovation spending.

Open

Supports United States small businesses through payroll tax offsets when they fund qualifying innovation activity.

Open

Funds basic research on how nerve agents, industrial chemicals and pesticides injure the nervous system, and where a countermeasure could interrupt it.

Open

Funds early, untested ideas in combat-relevant burn care meant to generate the preliminary data a later study would need.

Open

Funds turning preclinical burn-care findings into an actual product — a device, a drug, or a clinical practice guideline.

Open

Funds a human study of arthritis at whichever of two scales the evidence supports — a pilot or a full trial.

Open

Funds preclinical or animal arthritis research that's too applied to count as basic science and not yet ready for people.

Open

Funds a clinical trial of a new autism treatment, product or device, from a small proof-of-concept study up to a full efficacy trial.

Open

Funds a conceptually new, unproven idea in tick-borne disease research — not an incremental step on work that is already published or underway.

Open

Funds either a drug-discovery study or a clinical diagnostic approach for Lyme disease and other tick-borne diseases, aimed at something a clinic could use.

Open

Funds Princeton investigators moving university inventions toward licensing through proof-of-concept and prototype grants.

Open

Funds the one centre that coordinates a rare-disease genomics programme and gets its protocols, data and tools out to everybody else.

Open

Funds the centre that turns new molecular methods for rare-disease diagnosis into standards, best practices and a benchmarking dataset.

Open

Funds nothing — it hands over urine, plasma, serum and DNA from the national tobacco and health study. The research costs stay yours.

Open

Supports MTRAC life sciences teams with mid-stage funding that advances prototypes toward clinical and industry use.

Open

Supports recently tenured faculty with fellowships that enable bold cross-domain research pivots and sustained interdisciplinary leadership.

Open

Supports early life science teams at Michigan institutions by guiding proof of concept work toward development.

Open

Funds early-stage clinical trials in arthritis, musculoskeletal and skin disease. A trial is compulsory.

Open

Funds an early, unproven idea about bone marrow failure disease, even without preliminary data behind it.

Open

Funds mature bone marrow failure research, including drug-development groundwork, but not a clinical trial itself.